Data shows no increased risk of blood clot: AstraZeneca

LONDON: Following concerns raised over serious adverse events like blood clots related to its vaccine, AstraZeneca has reiterated the jab’s safety, saying it’s based “on clear scientific evidence’’.
The vaccine continues to be one of the primary vaccines being administered in India, with the government reportedly monitoring the side effects and adverse events.
A review of available safety data of over 17 million people inoculated in the EU and the UK has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia, in any defined age group, gender, batch or in any particular country, the company said. So far across the EU and UK, there have been 15 events of DVT and 22 events of pulmonary embolism reported among those given the vaccine (as of March 8). This is much lower than what would be expected to occur, and is similar across other vaccines, it said.
Astra’s chief medical officer Ann Taylor said: “...we are going beyond the standard practices for safety monitoring...”